Breast Cancer Clinical Trials in Nashville

Showing 221-240 of 707 trials

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

NCT05259696

This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.

OncologyMelanomaOvarian Cancer+14 more

Palleon Pharmaceuticals, Inc.69 participantsStarted Feb 2022

La Jolla, California, United States • Los Angeles, California, United States • Stanford, California, United States +10 more locations

RECRUITINGPhase 2< 1 mile

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

NCT04434040

The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: * Sacituzumab govitecan * Atezolizumab

Breast CancerTriple Negative Breast CancerResidual Cancer+1 more

Dana-Farber Cancer Institute40 participantsStarted Jul 2020

San Francisco, California, United States • Chicago, Illinois, United States • New Lenox, Illinois, United States +4 more locations

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Breast Cancer Trials in Other Cities

A Study of ADRX-0706 in Select Advanced Solid Tumors

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

MGC018 With or Without MGA012 in Advanced Solid Tumors

Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

MarginProbe 2.0 Data Collection Protocol

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

Other Conditions in Nashville